Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.
The trial is to evaluate the safety and efficacy of Bucillamine – an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
The Market Herald Canada’s Dave Jackson reports.
Weekly Update – Top Cannabis and Psychedelics News Stories
1 | Top Story: HAVN Life Sciences Inc. (CSE:HAVN) to supply psilocybin products for medical psilocybin & data project.
2 | MediPharm Labs Corp. (TSX:LABS) awarded favourable judgement in the Ontario Court of Justice.
3 | Algernon Pharmaceuticals Inc. (CSE:AGN) reports “additional positive data” from Phase 2 Study of Ifenprodil.
4 | Curaleaf Holdings Inc. (CSE:CURA) launches new product line targeting specific health & wellness categories.
5 | Nextleaf Solutions Ltd. (CSE:OILS) develops technology to produce distilled THC-free CBD oil.
Top Cannabis Stocks July 21 to July 27, 2022
1. T.HEXO | 13,734 views | Hexo Corp.
2. T.WEED |12,744 views | Canopy Growth Corp.
3. TLRY | 7,778 views | Tilray Brands Inc.
4. C.OILS | 3,824 views | Nextleaf Solutions Ltd.
5. C.TNY | 3,603 views | Tinley Beverage Co Inc.
6. T.TBP | 2,269 views | Tetra Bio-Pharma Inc.